The story of Sildenafil presents a challenging picture for those considering investment. While the initial release generated substantial profits, the end of its intellectual property protection opened the floodgates to generic versions, dramatically reducing sales. This creates a specific risk for firms relying on similar blockbuster products, sugg

The legacy of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, producing billions in revenue , its exclusivity read more period created a flood of lower-priced alternatives , significantly eroding its dominance. While specific businesses may attempt to capitalize on male sexual dysfun